ストックスクリーナーアプリを入手
0.487
0.21%
0.001
アフターアワーズ：
.49
0.003
+0.62%
前日終値:
$0.486
開ける：
$0.47
24時間の取引高:
56,602
Relative Volume:
0.09
時価総額：
$16.97M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.36%
1か月 パフォーマンス:
-30.13%
6か月 パフォーマンス:
-54.49%
1年 パフォーマンス:
-71.01%
1日の値動き範囲:
$0.47
$0.4997
1週間の範囲:
$0.4528
$0.5324
52週間の値動き範囲:
$0.2026
$4.06
Nkgen Biotech Inc Stock (NKGN) Company Profile
NKGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.487 | 16.97M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkgen Biotech Inc (NKGN) 最新ニュース
NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy? - Defense World
Midday Stock Roundup: Alignment Healthcare Rises on Update - Orange County Business Journal
Biotech Drama: Compliance Restored! Big Moves by NKGen Biotech! - Jomfruland.net
NKGen Biotech regains compliance with Nasdaq listing standards - Investing.com
NKGen Biotech secures $4.5M in convertible loan agreement - Investing.com India
NKGen Biotech secures $4.5M in convertible loan agreement By Investing.com - Investing.com Canada
NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why - Defense World
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - Asianet Newsable
NKGen Biotech Awards Stock Options to Executives - TipRanks
Head to Head Survey: HilleVax (NASDAQ:HLVX) versus NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech faces Nasdaq delisting over market value By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq delisting over market value - Investing.com
NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewswire
NKGen Biotech Secures $18M Bid for NKMax Acquisition, Expanding Global IP Rights - StockTitan
NKGen Biotech faces Nasdaq compliance issue By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq compliance issue - Investing.com India
NKGen Biotech Receives Notifications From Nasdaq… - Inkl
NKGen Biotech Receives Notifications From Nasdaq Related to - GlobeNewswire
NKGen Biotech Receives Nasdaq Non-Compliance Notice, Granted Extension for Q3 Filing | NKGN Stock News - StockTitan
OC500 2024: Paul Y. Song - Orange County Business Journal
NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire
NKGen Flat on Presentation of Alzheimer's Treatment - Baystreet.ca
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
NKGen Biotech Presents Phase 1/2a Troculeucel Data in - GlobeNewswire
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
NKGen Biotech avoids Nasdaq delisting with regained compliance - Investing.com India
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat ResultsCatheter Precision (AMEX:VTAK) - Benzinga
Navigating NKGN Stock: NKGen Biotech Inc Journey - The InvestChronicle
Post-Trade Analysis: NKGen Biotech Inc (NKGN) Slides -6.54, Closing at 0.23 - The Dwinnex
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - The Manila Times
NKGen Biotech undergoes dilutive stock issuance By Investing.com - Investing.com Canada
NKGen Biotech undergoes dilutive stock issuance - Investing.com India
NKGN stock touches 52-week low at $0.35 amid market challenges - Investing.com Australia
NKGen Biotech Announces Poster Presentations at the 17th - GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Market Watch Highlights: NKGen Biotech Inc (NKGN) Ends on an Upturn Note at 0.40 - The Dwinnex
NKGen Biotech directors resign after a year of service By Investing.com - Investing.com Australia
NKGen Biotech appoints new directors to its board By Investing.com - Investing.com South Africa
NKGen Biotech appoints new directors to its board - Investing.com India
NKGen Biotech Welcomes New Directors and Assigns Committees - TipRanks
Nkgen Biotech Inc (NKGN) 財務データ
Nkgen Biotech Inc (NKGN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):